Search

Now showing items 1-10 of 15

Opportunistic bilateral salpingectomy (OBS) for the prevention of ovarian cancer should be offered in the context of a clinical trial: FOR: There is lack of clarity on a number of key issues.

Manchanda, R; Menon, U (2016-02)

Impact of a decision aid about stratified ovarian cancer risk-management on women's knowledge and intentions: a randomised online experimental survey study.

Meisel, SF; Freeman, M; Waller, J; Fraser, L; Gessler, S; Jacobs, I; Kalsi, J; Manchanda, R; Rahman, B; Side, L;... (2017-11-16)

BACKGROUND: Risk stratification using genetic and other types of personal information could improve current best available approaches to ovarian cancer risk reduction, improving identification of women at increased risk ...

A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects.

Jervis, S; Song, H; Lee, A; Dicks, E; Harrington, P; Baynes, C; Manchanda, R; Easton, DF; Jacobs, I; Pharoah, PPD;... (2015-07)

BACKGROUND: Although BRCA1 and BRCA2 mutations account for only ∼27% of the familial aggregation of ovarian cancer (OvC), no OvC risk prediction model currently exists that considers the effects of BRCA1, BRCA2 and other ...

Importance of serial CA125 measurements over an absolute cut-off value for the detection of asymptomatic ovarian cancer in high-risk patients.

Dilley, J; Manchanda, R; Johnson, M; Rosenthal, AN; Gessler, S; Menon, U (2016-05)

The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

Manchanda, R; Drapkin, R; Jacobs, I; Menon, U (2012-02)

Opportunistic salpingectomy for prevention of ovarian cancer.

Manchanda, R (2017-05)

Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women.

Manchanda, R; Legood, R; Pearce, L; Menon, U (2015-12)

OBJECTIVE: To define risk thresholds for cost-effectiveness of risk-reducing salpingo-oophorectomy (RRSO) for ovarian cancer (OC) prevention in low/intermediate risk postmenopausal women. METHODS: A decision-analytic model ...

There is a need for routine peritoneal cytology at RRSO.

Manchanda, R; Drapkin, R; Menon, U (2013-01)

Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.

Cohen, PA; Powell, A; Böhm, S; Gilks, CB; Stewart, CJR; Meniawy, TM; Bulsara, M; Avril, S; Brockbank, EC; Bosse, T;... (2019-08)

OBJECTIVE: There is a need to develop and validate biomarkers for treatment response and survival in tubo-ovarian high-grade serous carcinoma (HGSC). The chemotherapy response score (CRS) stratifies patients into ...

A 3D tumor microenvironment regulates cell proliferation, peritoneal growth and expression patterns.

Loessner, D; Rockstroh, A; Shokoohmand, A; Holzapfel, BM; Wagner, F; Baldwin, J; Boxberg, M; Schmalfeldt, B; Lengyel, E; Clements, JA;... (2019-01)

Peritoneal invasion through the mesothelial cell layer is a hallmark of ovarian cancer metastasis. Using tissue engineering technologies, we recreated an ovarian tumor microenvironment replicating this aspect of disease ...